Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 447 Shares

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 447 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total value of $40,328.34. Following the completion of the sale, the insider now owns 347,731 shares in the company, valued at $31,372,290.82. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Jonathan Sheena also recently made the following trade(s):

• On Tuesday, March 5th, Jonathan Sheena sold 1,028 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $90,834.08.
• On Tuesday, February 6th, Jonathan Sheena sold 6,000 shares of Natera stock. The shares were sold at an average price of $70.00, for a total value of $420,000.00.
• On Monday, January 22nd, Jonathan Sheena sold 351 shares of Natera stock. The shares were sold at an average price of $68.16, for a total value of $23,924.16.
• On Wednesday, January 3rd, Jonathan Sheena sold 5,000 shares of Natera stock. The shares were sold at an average price of $60.30, for a total value of $301,500.00.

Natera Stock Up 1.1 %

NASDAQ NTRA traded up $1.00 on Friday, reaching $91.46. The stock had a trading volume of 971,264 shares, compared to its average volume of 1,783,625. The business has a 50 day moving average price of $78.46 and a 200 day moving average price of $61.25. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $96.24. The company has a market capitalization of $11.04 billion, a price-to-earnings ratio of -24.13 and a beta of 1.39.

Natera (NASDAQ:NTRA) last issued its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The firm had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. On average, analysts forecast that Natera, Inc. will post -2.43 EPS for the current fiscal year.

Institutional Trading of Natera

Institutional investors and hedge funds have recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Natera by 674.0% during the 4th quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 47,000 shares of the medical research company’s stock worth $2,944,000 after purchasing an additional 40,928 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after purchasing an additional 588,147 shares during the period. Perceptive Advisors LLC grew its position in Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after acquiring an additional 632,047 shares during the last quarter. American Trust bought a new stake in Natera during the 4th quarter worth approximately $213,000. Finally, Public Employees Retirement System of Ohio grew its position in Natera by 6.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 44,984 shares of the medical research company’s stock worth $2,818,000 after acquiring an additional 2,815 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several research analyst reports. The Goldman Sachs Group lifted their price target on Natera from $80.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Wolfe Research assumed coverage on Natera in a report on Wednesday, December 13th. They issued an “outperform” rating and a $70.00 target price on the stock. Raymond James cut Natera from a “strong-buy” rating to an “outperform” rating and lifted their target price for the stock from $68.00 to $85.00 in a report on Tuesday, February 20th. BTIG Research lifted their target price on Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a report on Friday, December 29th. Finally, Piper Sandler lifted their target price on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $78.36.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.